New PBS listing for migalastat (Galafold^®) for the treatment of Fabry disease

Page last updated: 19 August 2024

On 1 September 2024, migalastat (Galafold^®) will become available on the Pharmaceutical Benefits Scheme (PBS) for the treatment of Fabry disease under certain circumstances. 

Access to migalastat for new patients under the Life Saving Drugs Program (LSDP) will cease from 1 September 2024, with transition arrangements in place to facilitate access through the PBS for patients currently undergoing treatment.

Further information about the transition arrangements for treating physicians and patients can be found on the LSDP webpage.